BD (Becton, Dickinson and Company) has appointed Ferass Abuzaina as the worldwide president of its Surgery business unit, effective immediately. Abuzaina will lead the global strategic, operational, and commercial efforts of the Surgery division from its Warwick, RI headquarters, reporting to the executive vice president of the Interventional segment. With extensive experience at BD since 2013, including leadership roles in research, strategy, and business development, Abuzaina is expected to advance innovation and operational performance in Surgery. This leadership change aims to build on the unit's growth momentum and improve outcomes for patients and clinicians worldwide.
Following the appointment of Ferass Abuzaina as worldwide president of BD's Surgery unit, the company's stock shows positive momentum. On Pluang, BDX trades at USD 182.67, up 1.11% as of Oct 06, 2026, 17:51 WIB. The stock holds a market cap of $49.21 billion and a dividend yield of 2.32%, indicating steady investor interest during this leadership transition.
